Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Pre-exposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV infections. PrEP use has increased between 2013 and 2023. Multiple PrEP medications are available in ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...